ORCA Therapeutics B.V. to Start Highest Scheduled Dose in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients. Consistent Efficacy Data from First Cohort and Start New Indication. Additional funding secured.
‘s-Hertogenbosch, 5 March 2021.
Orca Therapeutics Announces Positive DSMB Review in Phase 1/2a Study of ORCA-010 in Treatment-Naïve Prostate Cancer Patients.
‘s-Hertogenbosch, 15 October 2020.
ORCA-010 SHOWS IMPRESSIVE FIRST-LINE PROSTATE CANCER DATA.
‘s-Hertogenbosch, 16 Juli 2020.
ORCA Therapeutics BV Announces Treatment of First Patient in a Phase I/IIa Study with ORCA-010 in Treatment-Naïve Patients with Localized Prostate Cancer.
‘s-Hertogenbosch, 23 December 2019.
ORCA Therapeutics receives approval from Spanish Interministerial Council of Genetically Modified Organisms to use ORCA-010 in a Phase I/IIa study in treatment-naïve prostate cancer patients.
‘s-Hertogenbosch, 4 December 2019.
ORCA Therapeutics receives approval from Health Canada to initiate a Phase I/IIa study with its oncolytic adenovirus ORCA-010 in treatment-naïve prostate cancer patients.
‘s-Hertogenbosch, 1 July 2019.
June 3-6, 2019
ORCA Therapeutics is attending the BIO International Convention (June 3-6) in Philadelphia. Get in touch and come see us!
The VIRION consortium held their 2nd year meeting in Schiphol on the 13 and 14 of September. ORCA met with the consortium partners and associated partners to discuss the progress made in the program. The overall program was presented and discussed with the H2020 REA representatives.
The progress of the consortium projects, ESR development program and collaboration was evaluated positively by the partners and REA representatives.
June 6, 2017
ORCA Therapeutics is attending the ASCO conference (June 2-6) in Chicago. Get in touch and come see us!
February 13, 2017
ORCA Therapeutics successfully completes preclinical studies on lead cancer drug candidate ORCA-010
September 25, 2016
VIRION Consortium first annual meeting held in Amsterdam
Interview with ORCA’s CSO Victor van Beusechem in LabVision (Dutch)
May 25, 2016
On May 27th ORCA’s CSO Victor van Beusechem will give his inaugural lecture entitled: “El Dorado beyond the horizon”
May 4, 2016
ORCA Therapeutics receives Horizon 2020 grant for developing innovative virotherapy for treatment of melanoma
April 1, 2016
ORCA Therapeutics raises €1.5 million for funding nonclinical evaluation and GMP production of their lead product ORCA-010
Issuance of a new U.S. patent covering ORCA’s T1 oncolytic adenovirus technology
Publication Demonstrates Strong Preclinical Efficacy of ORCA’s lead Compound ORCA-010 in Different Tumor Models
ORCA Therapeutics strengthens Scientific Advisory Board
ORCA Therapeutics granted Chinese Patent covering its T1 oncolytic adenovirus technology
ORCA Therapeutics strengthens its Patent Portfolio
ORCA Therapeutics receives up to € 5 Million Innovation Credit from Dutch Government
ORCA Therapeutics announces Grant of European Patent covering its proprietary T1 oncolytic adenovirus technology
ORCA Therapeutics receives VCN License
ORCA Therapeutics B.V. receives grant from SenterNovem